Skip to main content
. 2024 Aug 13;24:227. doi: 10.1186/s12911-024-02608-x

Table 3.

Similarities in preferred treatment options between EASL and HCV TS

2015
N = 21
2016
N = 67
2017
N = 80
2018
N = 114
2019
N = 181
2020
N = 100
No match (n, %) 5 (23.8) 13 (19.7) 27 (33.8) 14 (12.3) 17 (9.4) 16 (16.0)
1 match (n, %) 14 (66.7) 48 (72.7) 39 (48.8) 95 (83.3) 158 (87.3) 80 (80)
2 matches (n, %) 2 (9.5) 5 (7.6) 14 (17.5) 5 (4.4) 6 (3.3) 4 (4.0)

EASL European Association for the Study of the Liver, HCV TS Hepatitis C Therapy Selector